A phase lilt and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC)

Byers L.; Gerber D.; Peguero J.; Micklem D.; Yule M.; Lorens J. B.

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >A phase lilt and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC)

【24h】

A phase lilt and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC)

机译：BGB324的一期植物和药代动力学研究，一种选择性AXL抑制剂作为单一疗法，与先进的非小细胞肺癌患者组合与厄洛替尼相结合（NSCLC）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第null期|共2页
作者
Byers L.; Gerber D.; Peguero J.; Micklem D.; Yule M.; Lorens J. B.;
展开▼
作者单位

UT MD Anderson Canc Ctr Dept Thorac Head &

Neck Med Oncol Houston TX USA;

UT Southwestern Med Ctr Dallas TX USA;

Oncol Consultants Houston TX USA;

BerGenBio Bergen Norway;

BerGenBio Bergen Norway;

BerGenBio Bergen Norway;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A phase lilt and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) [J] . Byers L., Gerber D., Peguero J., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：选择性AXL抑制剂BGB324单药治疗并与厄洛替尼联用治疗晚期非小细胞肺癌（NSCLC）的阶段性升迁和药代动力学研究
2. MA 02.09 A Ph I/II Study of BGB324, a Selective AXL Inhibitor as Monotherapy and in Combination with Erlotinib in Advanced NSCLC [J] . D. Gibbons, L. Byers, D. Gerber, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：MA 02.09 A pH I / II研究BGB324，一种选择性AXL抑制剂作为单药治疗，以及在高级NSCLC中的Erlotinib组合
3. Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer [J] . Shimizu Toshio, Nishio Kazuto, Sakai Kazuko, Cancer chemotherapy and pharmacology. . 2020,第2期

机译：I期IM155安全性和药代动力学研究，一种有效的选择性Survivin抑制剂，与EGFR TKI难治晚期非小细胞肺癌患者组合。
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules [O] . Natalia Sutiman, Zhenxian Zhang, Eng Huat Tan, -1

机译：口服长春瑞滨联合厄洛替尼治疗晚期非小细胞肺癌（NSCLC）的I期研究采用两种不同的方案
7. MA 02.09 A Ph I/II Study of BGB324, a Selective AXL Inhibitor as Monotherapy and in Combination with Erlotinib in Advanced NSCLC [O] . D. Gibbons, L. Byers, D. Gerber, 2017

机译：MA 02.09 A pH I / II研究BGB324，一种选择性AXL抑制剂作为单药治疗，以及在高级NSCLC中的Erlotinib组合

A phase lilt and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC)

著录项

相似文献

相关主题

期刊订阅